Real‐world drug survival of Brodalumab, in patients with psoriasis switched from Ixekizumab: Results of a single centre retrospective study (BroSwitch)
Authors:
Open Access
- 18 May 2023
- journal article
- research article
- Published by Wiley in JEADV Clinical Practice
- Vol. 2 (3) , 510-517
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failedJournal of the American Academy of Dermatology, 2019
- The non-medical switching of prescription medicationsPostgraduate Medicine, 2019
- Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experienceBritish Journal of Dermatology, 2018
- No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasisJournal of Dermatological Treatment, 2018
- Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology AppraisalPharmacoEconomics, 2018
- Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapiesJournal of the American Academy of Dermatology, 2018
- Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trialThe Lancet, 2017
- Adalimumab therapy for psoriasis in real‐world practice: efficacy, safety and results in biologic‐naïve vs. non‐naïve patientsJournal of the European Academy of Dermatology and Venereology, 2012
- Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World PracticeDermatology, 2012
- Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: Comparison of patients according to their eligibility for major randomized clinical trialsArthritis & Rheumatism, 2006